Altered behavioral response to a D2 agonist, LY141865, in spontaneously hypertensive rats exhibiting biochemical and endocrine responses similar to those in normotensive rats

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 227; no. 2; pp. 354 - 359
• Main Authors: R W Fuller, S K Hemrick-Luecke, D T Wong, D Pearson, P G Threlkeld, M D Hynes, 3rd
• Format: Journal Article
• Language: English
• Published: United States American Society for Pharmacology and Experimental Therapeutics 01.11.1983
• Subjects: Animals; Behavior, Animal - drug effects; Corpus Striatum - analysis; Corpus Striatum - drug effects; Corticosterone - metabolism; Dopamine - metabolism; Ergolines - pharmacology; Hypertension - drug therapy; Motor Activity - drug effects; Neurotransmitter Agents - metabolism; Prolactin - metabolism; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine - drug effects; Receptors, Dopamine - metabolism
• ISSN: 0022-3565; 1521-0103

LY141865, a dopamine agonist selective for D2 dopamine receptors, caused hypomotility at low doses (0.01 and 0.1 mg/kg) and hypermotility at high doses (1 and 10 mg/kg) after i.p. injection into normotensive rats (WKY). In age-matched hypertensive rats (SHR), LY141865 caused hypomotility (not hypermotility) at all of these doses. The basal locomotor activity was higher in SHR than in WKY, but striatal concentrations of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, and of serotonin and its metabolite, 5-hydroxyindoleacetic acid, were not different between the two groups of rats. The specific binding of a dopamine receptor radioligand, tritiated pergolide, in striatum and mesolimbic regions, did not differ in SHR compared with WKY. In contrast to the lack of locomotor stimulation in SHR, other dopaminergic responses to LY141865 occurred in SHR as well as WKY. For instance, LY141865 decreased striatal and mesolimbic concentrations of 3,4-dihydroxyphenylacetic acid and homovanillic acid, increased striatal and mesolimbic concentrations of acetylcholine, decreased hypothalamic concentrations of epinephrine, increased serum corticosterone concentration and decreased serum prolactin concentration in SHR as in WKY. Because radioligand-labeled dopamine receptors and several LY141865 responses mediated by dopamine receptors did not differ appreciably in SHR compared with WKY, the lack of behavioral hypermotility in response to LY141865 in SHR may be due to abnormalities in some synaptic mechanisms beyond dopamine receptor activation that are involved in the expression of increased locomotion in response to the dopamine agonist.